BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26530743)

  • 21. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
    Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CyberKnife radiosurgery for stage I lung cancer: results at 36 months.
    Brown WT; Wu X; Fayad F; Fowler JF; Amendola BE; García S; Han H; de la Zerda A; Bossart E; Huang Z; Schwade JG
    Clin Lung Cancer; 2007 Sep; 8(8):488-92. PubMed ID: 17922973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung stereotactic body radiation therapy (SBRT) delivered over 4 or 11 days: a comparison of acute toxicity and quality of life.
    Jain S; Poon I; Soliman H; Keller B; Kim A; Lochray F; Yeung L; Cheung P
    Radiother Oncol; 2013 Aug; 108(2):320-5. PubMed ID: 23993401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC).
    Zimmermann FB; Geinitz H; Schill S; Thamm R; Nieder C; Schratzenstaller U; Molls M
    Acta Oncol; 2006; 45(7):796-801. PubMed ID: 16982542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non-Small-Cell Lung Cancer.
    Park HS; Harder EM; Mancini BR; Decker RH
    J Thorac Oncol; 2015 May; 10(5):832-837. PubMed ID: 25634007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
    Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
    Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
    Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
    Bezjak A; Paulus R; Gaspar LE; Timmerman RD; Straube WL; Ryan WF; Garces YI; Pu AT; Singh AK; Videtic GM; McGarry RC; Iyengar P; Pantarotto JR; Urbanic JJ; Sun AY; Daly ME; Grills IS; Sperduto P; Normolle DP; Bradley JD; Choy H
    J Clin Oncol; 2019 May; 37(15):1316-1325. PubMed ID: 30943123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery?
    Onishi H; Shirato H; Nagata Y; Hiraoka M; Fujino M; Gomi K; Karasawa K; Hayakawa K; Niibe Y; Takai Y; Kimura T; Takeda A; Ouchi A; Hareyama M; Kokubo M; Kozuka T; Arimoto T; Hara R; Itami J; Araki T
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1352-8. PubMed ID: 20638194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation.
    Hodge W; Tomé WA; Jaradat HA; Orton NP; Khuntia D; Traynor A; Weigel T; Mehta MP
    Acta Oncol; 2006; 45(7):890-6. PubMed ID: 16982555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
    Mangona VS; Aneese AM; Marina O; Hymas RV; Ionascu D; Robertson JM; Gallardo LJ; Grills IS
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):124-32. PubMed ID: 25442337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
    Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
    Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
    Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
    Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
    Song SY; Choi W; Shin SS; Lee SW; Ahn SD; Kim JH; Je HU; Park CI; Lee JS; Choi EK
    Lung Cancer; 2009 Oct; 66(1):89-93. PubMed ID: 19168260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.